Delivery Order SPE2DB24D2205-SPE2DB25FEGMP
- Not listed
- The Defense Logistics Agency awarded a $15,814.20 delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyvanse 10 mg capsules (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 26, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Vyvanse 10 mg capsules (100-count units) with a ceiling value of $5,729.59. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is set to conclude on June 20, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a ceiling value of $1,100.64. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 19, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply transaction under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Vyvanse 20 mg capsules (100-count units) with a ceiling value of $7,938.11. This is a firm fixed-price delivery order with no set-aside designation, indicating the award resulted from open competition. The contract is scheduled for ultimate completion on August 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 20 mg capsules (100-count units) with a ceiling value of $2,090.42. The order, classified as a child contract under a firm fixed-price arrangement with no set-aside designation, is scheduled for completion by July 23, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. This delivery order falls under AmerisourceBergen's broader Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100-count units) on August 25, 2025, with a ceiling value of $1,781.07 and an ultimate completion date of August 26, 2025. This contract was awarded competitively with no set-aside designation and utilizes firm fixed-price pricing. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Vyvanse 50 mg capsules (100-count) under a firm fixed-price contract with a ceiling value of $5,192.54. The order, which is classified as a child contract under a larger indefinite delivery vehicle, carries an ultimate completion date of July 24, 2025. This delivery order was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) at a ceiling value of $2,079.25. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyvanse 40 mg capsules (100 count units). This competitively awarded, firm fixed-price delivery order has a ceiling value of $2,517.96 and an ultimate completion date of August 26, 2025. The contract represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEGMPDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Vyvanse 10 mg capsules (100 count) under a firm fixed-price contract with a ceiling value of $15,024.87. This is a child contract with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement needs through the Defense Logistics Agency's Medical Supply Chain. The company's extensive federal contract portfolio demonstrates its capability to supply comprehensive pharmaceutical products and medical supplies to military and veteran healthcare systems, including specialty medications, generic drugs, vaccines, and medical devices. This particular delivery order for Vyvanse—a prescription stimulant medication commonly used in military and federal healthcare settings—reflects the company's ongoing role in supporting the Defense Health Agency and other government healthcare systems with essential pharmaceutical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.0k | 8/19/25 |